TY  - JOUR
A1  - Cremer, Sebastian
A1  - Jakob, Carolin Ellen Marianne
A1  - Berkowitsch, Alexander
A1  - Borgmann, Stefan
A1  - Pilgram, Lisa
A1  - Tometten, Lukas
A1  - Claßen, Annika
A1  - Wille, Kai
A1  - Weidlich, Simon
A1  - Grüner, Beate
A1  - Dimmeler, Stefanie
A1  - Maßberg, Steffen
A1  - Rieg, Siegbert
A1  - Zeiher, Andreas M.
T1  - Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry
T2  - Clinical research in cardiology
N2  - Aims: SARS-CoV-2 infection is associated with adverse outcomes in patients with cardiovascular disease. Here, we analyzed whether specific biomarkers predict the clinical course of COVID-19 in patients with cardiovascular comorbidities. Methods and results: We enrolled 2147 patients with SARS-CoV-2 infection which were included in the Lean European Open Survey on SARS-CoV‑2 (LEOSS)-registry from March to June 2020. Clinical data and laboratory values were collected and compared between patients with and without cardiovascular comorbidities in different clinical stages of the disease. Predictors for mortality were calculated using multivariate regression analysis. We show that patients with cardiovascular comorbidities display significantly higher markers of myocardial injury and thrombo-inflammatory activation already in the uncomplicated phase of COVID-19. In multivariate analysis, elevated levels of troponin [OR 1.54; (95% CI 1.22–1.96), p < 0.001)], IL-6 [OR 1.69 (95% CI 1.26–2.27), p < 0.013)], and CRP [OR 1.32; (95% CI 1.1–1.58), p < 0.003)] were predictors of mortality in patients with COVID-19. Conclusion: Patients with cardiovascular comorbidities show elevated markers of thrombo-inflammatory activation and myocardial injury, which predict mortality, already in the uncomplicated phase of COVID-19. Starting targeted anti-inflammatory therapy and aggressive anticoagulation already in the uncomplicated phase of the disease might improve outcomes after SARS-CoV-2 infection in patients with cardiovascular comorbidities.
KW  - Inflammation
KW  - COVID-19
KW  - Myocardial injury
KW  - Coagulation
KW  - Mortality
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63629
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-636299
SN  - 1861-0692
N1  - Open Access funding enabled and organized by Projekt DEAL. The study was supported by the German Center for Infection Research, the Pitzer Foundation to J.V., and the German Center for Cardiovascular Research DZHK, Berlin, Germany to A.B.
VL  - 110
IS  - 7
SP  - 1029
EP  - 1040
PB  - Springer
CY  - Berlin
ER  -